Thrombotic thrombocytopenic purpura. Experience in 18 cases and literature review;Púrpura trombótico trombocitopénico: Revisión de la literatura a partir de 18 casos

Revista Medica de Chile

Volumn 136, Issue 12, 2008, Pages 1518-1527

  Eymin, Gonzalo L ^a   Andrade, Maricarmen A ^b   Andresen, Max H ^c   Pereira, Jaime G ^d  

^a Departamento de Medicina Interna   (Chile)

^b Residente de Geriatría ^*  (Spain)

^c Departamento de Medicina Intensiva

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Plasmapheresis; Purpura; Thrombotic thrombocytopenic; Von Willebrand factor

Indexed keywords

ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; ENZYMOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; PLASMAPHERESIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; THROMBOTIC THROMBOCYTOPENIC PURPURA; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VERY ELDERLY;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMAPHERESIS; PROSPECTIVE STUDIES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RETROSPECTIVE STUDIES;

EID: 62849112770     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Moake J. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
2. Liu L, Choi H, Bernardo A, Bergeron A, Nolasco L, Ruan C et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005; 3: 2536-44.
3. Han-Mou Tsai. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006; 57: 419-36.
4. Han-Mou Tsai. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003; 14: 1072-81.
5. Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal G et al. Nonneutralizing IgM and IgG antibodies to Von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102: 3241-3.
6. Hymes K, Karpatkin S. Human immunodeficiency virus infection and thrombotic microangiopathy. Semin Hematol 1997; 34: 117-25.
7. Veyradier A, Obert B, Houllier A, Meyer D, Girma J. Specific Von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-72.
8. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle P, Brenner B et al. Von Willebrand Factor-Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndrome. N Engl J Med 1998; 339: 1578-84.
9. Moore J, Hayward C, Warkentin T, Kelton J. Decreased Von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 1842-6.
10. Mannucci P, Canciani M, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloproteinase that cleaves Von Willebrand factor. Blood 2001; 98: 2730-5.
11. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-3.
12. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwacura Y, Ishiwaka A et al. Severe secondary deficiency of Von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-34.
13. Rock G, Shumack K, Buskard N, Blanchette V, Kelton J, Fair R et al. Comparison of plasma Exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393-7.
14. Rock G, Shumak K, Kelton J, Blanchette V, Buskard N, Nair R et al. Thrombotic thrombocytopenic purpura: Outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 1992; 32: 710-4.
15. Brunskill S, Tusold A, Benjamin S, Stanworth SJ, Murphy M. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med 2007; 17: 17-35.
16. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake M. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-8.
17. Zeigler Z, Shadduck R, Gryn JF, Rintels P, George J, Besa E et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura. J Clin Apheresis 2001; 16: 19-22.
18. Rock G, Anderson D, Clark W, Leblond P, Palmer D, Sternbach M et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005; 129: 79- 86.
19. Allford S, Hunt B, Rose P, Machin S. Guidelines on the diagnosis and management of the thrombotic microangiopatic haemolytic anemias. Br J Haematol 2003; 120: 556-73.
20. George J. How I treat patients with Thrombotic thrombocytopenic purpura- hemolytic uremic syndrome. Blood 2000; 96: 1223-9.
21. Bell W, Braine H, Ness P, Kickler T. Improved survival in thrombotic thrombocytopenic purpura- hemolytic uremic syndrome. N Engl J Med 1991; 325: 398-403.
22. George J. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-35.
23. Cataland S, Jin M, Ferketich A, Kennedy M, Kraut E, George J, Wu H. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136: 146-9.
24. Fakhouri F, Vernant J, Veyradier A, Wolf M, Kaplanski G, Binaut R et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-7.
25. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai H. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124: 787-95.
26. Ziman A, Mitri M, Klapper E, Pepkowitz S, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion 2005; 45: 41-9.
27. Allan D, Kovacs M, Clark W. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001; 86: 844-50.
28. Zheng X, Pallera A, Goodnough L, Sadler J, Blinder M. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138: 105-8.
29. Fakhouri F, Teixeira L, Delarue R, Grünfeld J, Veyradier A. Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide. Ann Intern Med 2004; 140: 314-5.
30. Ramírez N, García J, Andreu J, Martino M. Thrombotic thrombocytopenic purpura, systemic lupus erythematosus and rescue treatment with cyclophosphamide. Rev Clin Esp 2005; 205: 520-2.
31. Kapoulas S, Liakos S, Karkavelas G, Ageloudi M, Grekas D, Giannoulis E. Thrombotic thrombocytopenic purpura associated wit rapidly progressive lupus nephritis: report of two case. Clin Nephrol 2005; 63: 297-301.
32. George J, Woodson R, Kiss J, Kojouri K, Vesely S. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the transfusion Medicine/ Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immunemediated disorders. J Clin Apher 2006; 21: 49-56.
33. Rizvi M, Vesely S, George J, Chandler L, Duvall D, Smith J, Gilcher R. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2000; 40: 896-901.